| ||||||||||||||
Former Names NOD.CBALs-Hc1/Lt (Changed: 06-SEP-06 ) NOD.CBALs-Hc1 (Changed: 20-JAN-05 ) Type Congenic; Mutant Strain; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Background Strain NOD/ShiLt Donor Strain CBA/JLsLt H2 Haplotype g7 Generation N10F13p Donating Investigator Edward Leiter, The Jackson Laboratory Appearance
albino, pink eyed
Related Genotype: A/A Tyrc/TyrcDescription
This NOD/Lt congenic strain is carrying Chr 2 alleles derived from CBA/Ls including Hc1. Diabetes onset and incidence is the same as NOD/Lt.Development
C5 hemolytic complement located on Chr. 2 was transfered from CBA/Ls to NOD/Lt for 10 generations replacing the defective Hc0 allele expressed in NOD/Lt. In 2006, the T1DR received homozygous NOD.CBALs-Hc1/Lt at generation N10F11.
| Control | ||
|---|---|---|
| 001976 NOD/ShiLtJ | ||
| Considerations for Choosing Controls | ||
Strains carrying Hc1 allele
000470 AK.M-H2m H2-T18a/nSnJ 005308 B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 000463 B10.D2-Hc1 H2d H2-T18c/nSnJ 003147 B10.D2-Hc1 H2d H2-T18c/nSnJ-Tg(DO11.10)10Dlo/J View Strains carrying Hc1 (4 strains)
Strains carrying other alleles of Hc
000645 A/HeJ 000646 A/J 000647 A/WySnJ 000648 AKR/J 000460 B10.D2-Hc0 H2d H2-T18c/o2SnJ 000461 B10.D2-Hc0 H2d H2-T18c/oSnJ 000657 CE/J 000671 DBA/2J 007048 DBA/2J-Gpnmb+/SjJ 001800 FVB/NJ 001491 FVB/NMob 000674 I/LnJ 001303 NOD.CB17-Prkdcscid/J 001976 NOD/ShiLtJ 000684 NZB/BlNJ 000682 RF/J 000688 ST/bJ 000689 SWR/J View Strains carrying other alleles of Hc (18 strains)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Hc1 relatedDiabetes and Obesity Research
Type 1 Diabetes (IDDM) Analysis Strains
NOD/ShiLtJ Non-MHC Congenics
Research Tools
Diabetes and Obesity Research
Immunology and Inflammation Research
Immunology and Inflammation Research
Immunodeficiency
specific complement deficiency, control
Research Tools
Immunology and Inflammation Research
specific complement deficiency, C5 complement, control
| Allele Symbol | Hc1 | ||
|---|---|---|---|
| Allele Name | sufficient | ||
| Allele Type | Not Applicable | ||
| Common Name(s) | C5 sufficient; C5-s; C5-suf; | ||
| Gene Symbol and Name | Hc, hemolytic complement | ||
| Chromosome | 2 | ||
| Gene Common Name(s) | C5; C5a; CPAMD4; FLJ17816; FLJ17822; He; MGC142298; | ||
| General Note |
Hc was identified as a candidate gene for Abhr2 in a microarray analysis of lung mRNA from A/J, C3H/HeJ, and (A/J x C3H/HeJ)F1 x A/J backcross animals. Hc genotype shows statistically significant correlation to allergen-induced bronchial hyperresponsive phenotype. The C3H/HeJ allele does not have the 2 bp deletion and is associated with resistance to allergen-induced bronchial hyperresponsiveness. (J:108211) | ||
| Molecular Note | This allele does not contain the 2 base "TA" deletion found in the Hc0 allele and is found in the following mouse strains BALB/cJ, C57BL/6J, DBA/1J, and B10.D2/nSnJ. This is equivalent to the wild-type allele. [MGI Ref ID J:23983] | ||
This strain will not have a genotyping protocol or one is not currently available.
Helpful Links
Genotyping resources and troubleshooting
Chen J; Reifsnyder PC; Scheuplein F; Schott WH; Mileikovsky M; Soodeen-Karamath S; Nagy A; Dosch MH; Ellis J; Koch-Nolte F; Leiter EH. 2005. 'Agouti NOD': identification of a CBA-derived Idd locus on Chromosome 7 and its use for chimera production with NOD embryonic stem cells. Mamm Genome 16(10):775-83. [PubMed: 16261419] [MGI Ref ID J:102639]
Hc1 relatedActor JK; Breij E; Wetsel RA; Hoffmann H; Hunter RL Jr; Jagannath C. 2001. A role for complement C5 in organism containment and granulomatous response during murine tuberculosis. Scand J Immunol 53(5):464-74. [PubMed: 11309154] [MGI Ref ID J:103981]
Addis-Lieser E; Kohl J; Chiaramonte MG. 2005. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol 175(3):1894-902. [PubMed: 16034133] [MGI Ref ID J:107269]
Girardi G; Berman J; Redecha P; Spruce L; Thurman JM; Kraus D; Hollmann TJ; Casali P; Caroll MC; Wetsel RA; Lambris JD; Holers VM; Salmon JE. 2003. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112(11):1644-54. [PubMed: 14660741] [MGI Ref ID J:86845]
Karp CL; Grupe A; Schadt E; Ewart SL; Keane-Moore M; Cuomo PJ; Kohl J; Wahl L; Kuperman D; Germer S; Aud D; Peltz G; Wills-Karp M. 2000. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 1(3):221-6. [PubMed: 10973279] [MGI Ref ID J:108211]
Kawikova I; Paliwal V; Szczepanik M; Itakura A; Fukui M; Campos RA; Geba GP; Homer RJ; Iliopoulou BP; Pober JS; Tsuji RF; Askenase PW. 2004. Airway hyper-reactivity mediated by B-1 cell immunoglobulin M antibody generating complement C5a at 1 day post-immunization in a murine hapten model of non-atopic asthma. Immunology 113(2):234-45. [PubMed: 15379984] [MGI Ref ID J:92933]
Kirimanjeswara GS; Mann PB; Pilione M; Kennett MJ; Harvill ET. 2005. The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4. J Immunol 175(11):7504-11. [PubMed: 16301658] [MGI Ref ID J:122156]
Mahesh J; Daly J; Cheadle WG; Kotwal GJ. 1999. Elucidation of the early events contributing to zymosan-induced multiple organ dysfunction syndrome using MIP-1alpha, C3 knockout, and C5-deficient mice. Shock 12(5):340-9. [PubMed: 10565608] [MGI Ref ID J:59655]
Miller CG; Cook DN; Kotwal GJ. 1996. Two chemotactic factors, C5a and MIP-1alpha, dramatically alter the mortality from zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to MODS while MIP-1alpha has a protective role. Mol Immunol 33(14):1135-7. [PubMed: 9047380] [MGI Ref ID J:38592]
Mocco J; Mack WJ; Ducruet AF; Sosunov SA; Sughrue ME; Hassid BG; Nair MN; Laufer I; Komotar RJ; Claire M; Holland H; Pinsky DJ; Connolly ES Jr. 2006. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 99(2):209-17. [PubMed: 16778128] [MGI Ref ID J:123658]
Mori L; de Libero G. 1998. Genetic control of susceptibility to collagen-induced arthritis in T cell receptor beta-chain transgenic mice. Arthritis Rheum 41(2):256-62. [PubMed: 9485083] [MGI Ref ID J:134111]
Moulton RA; Mashruwala MA; Smith AK; Lindsey DR; Wetsel RA; Haviland DL; Hunter RL; Jagannath C. 2007. Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice. J Leukoc Biol 82(4):956-67. [PubMed: 17675563] [MGI Ref ID J:125190]
Niculescu T; Weerth S; Niculescu F; Cudrici C; Rus V; Raine CS; Shin ML; Rus H. 2004. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J Immunol 172(9):5702-6. [PubMed: 15100315] [MGI Ref ID J:89686]
Nilsson UR; Muller-Eberhard HJ. 1967. Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med 125(1):1-16. [PubMed: 4959665] [MGI Ref ID J:5016]
Ooi YM; Colten HR. 1979. Genetic defect in secretion of complement C5 in mice. Nature 282(5735):207-8. [PubMed: 492335] [MGI Ref ID J:6214]
Patel SN; Berghout J; Lovegrove FE; Ayi K; Conroy A; Serghides L; Min-oo G; Gowda DC; Sarma JV; Rittirsch D; Ward PA; Liles WC; Gros P; Kain KC. 2008. C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J Exp Med 205(5):1133-43. [PubMed: 18426986] [MGI Ref ID J:136298]
Pritchard MT; McMullen MR; Stavitsky AB; Cohen JI; Lin F; Medof ME; Nagy LE. 2007. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 132(3):1117-26. [PubMed: 17383432] [MGI Ref ID J:128218]
Redecha P; Tilley R; Tencati M; Salmon JE; Kirchhofer D; Mackman N; Girardi G. 2007. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110(7):2423-31. [PubMed: 17536017] [MGI Ref ID J:147022]
Tanaka D; Kagari T; Doi H; Shimozato T. 2006. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119(2):195-202. [PubMed: 16836650] [MGI Ref ID J:118551]
Wetsel RA; Fleischer DT; Haviland DL. 1990. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J Biol Chem 265(5):2435-40. [PubMed: 2303408] [MGI Ref ID J:23983]
Wheat WH; Wetsel R; Falus A; Tack BF; Strunk RC. 1987. The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency. J Exp Med 165(5):1442-7. [PubMed: 3572304] [MGI Ref ID J:8690]
Younger JG; Shankar-Sinha S; Mickiewicz M; Brinkman AS; Valencia GA; Sarma JV; Younkin EM; Standiford TJ; Zetoune FS; Ward PA. 2003. Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am J Respir Cell Mol Biol 29(4):432-8. [PubMed: 14500254] [MGI Ref ID J:94613]
Zhou W; Farrar CA; Abe K; Pratt JR; Marsh JE; Wang Y; Stahl GL; Sacks SH. 2000. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 105(10):1363-71. [PubMed: 10811844] [MGI Ref ID J:120567]
Currently there no information available for this strain. This may be due to the supply level of this strain.
| Pricing for USA, Canada and Mexico shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $1900.00 Cryopreserved Embryos $1600.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Pricing for International shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $2470.00 Cryopreserved Embryos $2080.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Standard Supply | Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| 001976 NOD/ShiLtJ | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.